Enfusion, Inc. Quarterly Cost of Revenue in USD from Q1 2021 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The aggregate cost of goods produced and sold and services rendered during the reporting period.
Summary
Enfusion, Inc. quarterly/annual Cost of Revenue history and growth rate from Q1 2021 to Q3 2024.
  • Enfusion, Inc. Cost of Revenue for the quarter ending September 30, 2024 was $16.3M, a 12.6% increase year-over-year.
  • Enfusion, Inc. Cost of Revenue for the twelve months ending September 30, 2024 was $64.1M, a 15.9% increase year-over-year.
  • Enfusion, Inc. annual Cost of Revenue for 2023 was $57.6M, a 22.4% increase from 2022.
  • Enfusion, Inc. annual Cost of Revenue for 2022 was $47.1M, a 47.9% increase from 2021.
  • Enfusion, Inc. annual Cost of Revenue for 2021 was $31.8M, a 49.1% increase from 2020.
Cost of Revenue, Trailing 12 Months (USD)
Cost of Revenue, Quarterly (USD)
Cost of Revenue, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $64.1M $16.3M +$1.83M +12.6% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-04
Q2 2024 $62.3M $16M +$1.75M +12.3% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-06
Q1 2024 $60.5M $16.2M +$2.87M +21.6% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 $57.6M $15.6M +$2.33M +17.5% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-12
Q3 2023 $55.3M $14.5M +$2.53M +21.2% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-04
Q2 2023 $52.8M $14.2M +$3.36M +31% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-06
Q1 2023 $49.4M $13.3M +$2.32M +21.1% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 $47.1M $13.3M +$3.13M +30.8% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-12
Q3 2022 $44M $12M +$3.88M +47.9% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-07
Q2 2022 $40.1M $10.8M +$4.07M +60.1% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 $36M $11M +$4.17M +61.3% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q4 2021 $31.8M $10.2M Oct 1, 2021 Dec 31, 2021 10-K 2024-03-12
Q3 2021 $8.1M Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 $6.78M Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-10
Q1 2021 $6.81M Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-13
* An asterisk sign (*) next to the value indicates that the value is likely invalid.